



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Stine Friis
✉ sf@evaxion-biotech.com

RECEIVED 07 September 2023
ACCEPTED 08 September 2023
PUBLISHED 14 September 2023

CITATION
Barrio-Calvo M, Kofoed SV, Holste SC,
Sørensen AB, Viborg N, Kringelum JV,
Kleine-Kohlbrecher D, Steenmans CS,
Thygesen CB, Rønø B and Friis S (2023)
Corrigendum: Targeting neoantigens to
APC-surface molecules improves the
immunogenicity and anti-tumor efficacy of
a DNA cancer vaccine.
Front. Immunol. 14:1290431.
doi: 10.3389/fimmu.2023.1290431

COPYRIGHT
© 2023 Barrio-Calvo, Kofoed, Holste,
Sørensen, Viborg, Kringelum, Kleine-
Kohlbrecher, Steenmans, Thygesen, Rønø
and Friis. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine

Marina Barrio-Calvo, Søren Vester Kofoed, Sofie Cens Holste, Anders Bundgård Sørensen, Nadia Viborg, Jens Vindahl Kringelum, Daniela Kleine-Kohlbrecher, Christian Skjødt Steenmans, Christian Bahne Thygesen, Birgitte Rønø and Stine Friis*

Evaxion Biotech, Hørsholm, Denmark

KEYWORDS

APC-targeting, CCL19, neoantigens, DNA vaccine, cancer immunotherapy

A Corrigendum on

Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine

by Barrio-Calvo M, Kofoed SV, Holste SC, Sørensen AB, Viborg N, Kringelum JV, Kleine-Kohlbrecher D, Steenmans CS, Thygesen CB, Rønø B and Friis S (2023) *Front. Immunol.* 14:1234912. doi: 10.3389/fimmu.2023.1234912

In the published article, there was an error in the Funding statement. The authors inadvertently omitted a funding disclosure that should have been included in the funding section of the manuscript. The correct Funding statement appears below.

Funding

The Innovation Fund Denmark partially funded MB-C (1044-00028B) and NV (5189-00187B). The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.